Cannabidiol 2 is under clinical development by Avecho Biotechnology and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cannabidiol 2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol 2 overview

Cannabidiol is under development for the treatment of osteoarthritis pain and dermatology. It is administered topically in the form of gel. The drug candidate is being developed based on Tocopheryl Phosphate Mixture (TPM) platform. It acts by targeting cannabinoid receptor 1 and cannabinoid receptor 2.

Avecho Biotechnology overview

Avecho Biotechnology (Avecho), formerly Phosphagenics, is a research-driven biotechnology firm that develops and commercializes human and animal health products. The company’s drug delivery technology tocopheryl phosphate mixture (TPM) is derived from vitamin E using a proprietary and patented process that improves the solubility and oral, dermal and transdermal adsorption of drugs and nutrients. Avecho’s product portfolio includes daptomycin, diclofenac gel, propofol injection, oxymorphone patch, oxycodone patch, tretinoin gel and transdermal opioid patches. The company also develops cannabinoid products in partnership with major drug manufacturers. It markets products under Vital ET and TPM brand names. It has business presence in Australia, India, Switzerland, and the US. Avecho is headquartered in Clayton, Victoria, Australia.

For a complete picture of Cannabidiol 2’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.